President Trump’s administration has slammed the brakes on development of messenger RNA (mRNA) vaccines, which proved their ...

BioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy ...

Researchers in Australia use COVID-era mRNA technology to expose hidden HIV in white blood cells, offering hope for a future ...

The recent downturn in biotech has battered Massachusetts’ world-renowned sector, and the political climate has only made it ...

The BioNTech SE acquisition of CureVac N.V. brings together complementary technologies, as both are developing mRNA ...

RNA gene scissors (CRISPR-Cas13) are gaining significant attention as a next-generation gene therapy with fewer side effects.

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a welcome win.

After soaring to success in the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) experienced a reversal of fortune ...

Moderna vaulted to the forefront of biotech, becoming a major pillar of the region’s economy. But Robert F. Kennedy Jr.’s ...